Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?
TheFly reported on June 24 that Raymond James initiated coverage of MPLT with a Strong Buy rating and a $46 price target.
Maplight Therapeutics Inc. (MPLT)
Market is closed
Sector: Healthcare
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.86 | 9,920 | $177,171.20 | 25,000 | 2026-02-20 | Filing | |
| $17.57 | 4,422 | $77,694.54 | 15,080 | 2026-02-19 | Filing | |
| $17.48 | 10,658 | $186,301.84 | 10,658 | 2026-02-18 | Filing | |
| $17.89 | 14,124 | $252,678.36 | 14,124 | 2026-02-10 | Filing | |
| $17.00 | 952,941 | $16,199,997.00 | 3,686,622 | 2025-10-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $37.90 | 16,779 | $635,924.10 | 1,246,455 | 2026-07-17 | Filing | |
| $37.96 | 92 | $3,492.32 | 1,263,234 | 2026-07-16 | Filing | |
| $37.26 | 28,091 | $1,046,670.66 | 1,263,326 | 2026-07-16 | Filing | |
| $36.46 | 40,899 | $1,491,177.54 | 1,291,417 | 2026-07-16 | Filing | |
| $37.54 | 90 | $3,378.60 | 1,332,316 | 2026-07-15 | Filing |
News See All
10 Best Biotech Stocks to Buy According to Analysts
Biotechnology is enjoying one of its strongest years in recent times, which is mostly fueled by a rebound in capital markets, rising merger activity, and renewed investor confidence.
8 Must-Buy Small Cap Stocks to Buy
After many years of large capitalization companies dominating the US equities market, time is ripe for rotation.
8 Healthcare Stocks Insiders Are Buying
Insider buying tends to draw attention because insiders know their companies best.
Hedge Fund Resource Center